Anzeige
Mehr »
Login
Donnerstag, 05.08.2021 Börsentäglich über 12.000 News von 668 internationalen Medien
Relay Medical im Fokus der Sportwelt! Federer, Nadal & Medvedev...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Endpoints News

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
13:35UK re-investigates Pfizer's eye-popping price gouging on an epilepsy drug
13:35A small vaccine developer favored by the UK government in Covid-19 touts a PhIII first in chikungunya
10:35Bayer nabs star biotech Vividion with a $2B buyout and an 'arms-length' pact, pulling a partner out of the IPO conga line
10:35Science pioneer, pharma research chief, global health advocate and biotech entrepreneur Tadataka 'Tachi' Yamada has died
MiZymergen's sudden implosion shocked biopharma. A lingering loan could make things even worse
MiHHS extends Aduhelm investigation into the accelerated approval pathway, wading into a brewing controversy
MiShares of BeyondSpring skyrocket on new, positive cancer drug trial results
MiPfizer puts the pressure on Eli Lilly's JAK inhibitor Olumiant with new data in alopecia areata
MiAmgen adds new NC plant to the list as part of $1B manufacturing expansion plans stateside
MiAmgen may see $3B+ in additional taxes; EQRx, AbCellera ink antibody development deal
MiBiogen, Eisai are pushing for another accelerated Alzheimer's OK - this time for BAN2401
MiSoftBank claims $5B stake in Roche amid grand plans to invest in biotech - reports
MiSamantha Du's Zai Lab inks surprising research collab with Schrödinger for DNA damage drug
MiCovid-19 roundup: Early fall approval date of Pfizer-BioNTech jab still anticipated; EU buys 200m doses of Novavax vaccine
MiFDA slaps back small-cap's bid to repurpose 50-year-old chemotherapy
MiJeff Bluestone just raised $265M to develop curative cell therapies. We asked him how
MiArdelyx chops a third of its staff after stock-crushing failure in chronic kidney disease
MiAmgen halts a PhI for FLT3 BiTE while resuming dosing on another
DiSynbio unicorn Zymergen jettisons founding CEO, cuts guidance as customers report lead product doesn't work
DiRoche's PD-L1 franchise player nabs priority review; World's first psychedelics research institute opens in Australia
DiFast-growing BeiGene blueprints 42-acre R&D and manufacturing campus in the US, with plans to hire 'hundreds'
DiEli Lilly: As donanemab filing approaches, execs 'even more confident' in data package
DiSage drops a pair of late-stage tests for Biogen-partnered depression drug, raising the stakes on a final trial
DiOpinion: Pricing info with new drug approvals: Time for transparency
DiJ&J, GV back a new single-cell approach for tackling inflammatory diseases and hacking the tumor microenvironment